基于网络药理学探究泽泻的治疗潜能及作用机制
Exploring the Therapeutic Potential and Mechanism of Alismatis Rhizoma Based on Network Pharmacology
DOI: 10.12677/PI.2022.112016, PDF,    科研立项经费支持
作者: 詹家仪, 钟 勰, 张 瑶, 毛 涵, 陈向云, 李尧锋*：贵州中医药大学，贵州 贵阳；詹家国：天津中医药大学，天津；谭雅琴：湖南中医药大学，湖南 长沙
关键词: 泽泻；治疗潜能；作用机制；网络药理学；Alismatis Rhizoma； Therapeutic Potential； Mechanism； Network Pharmacology
摘要: 目的：探究泽泻治疗疾病的潜能及作用机制。方法：通过TCMSP数据库获取泽泻的化学成分及作用靶点。利用String数据库构建蛋白互作(PPI)网络，通过Cytoscape软件对PPI网络进行可视化处理并筛选出核心靶点。通过DAVID数据库进行GO和KEGG通路富集分析。使用CTD数据库预测泽泻治疗疾病的潜能，再利用Cytoscape软件构建泽泻“成分–靶点–通路–疾病”网络，分析其作用机制。结果：筛选出泽泻有效化学成分27个，如大黄素、泽泻醇A、23-乙酰泽泻醇B、环氧泽泻烯等，作用靶点73个，主要涉及TNF、II型糖尿病、乙型肝炎、神经活性配体–受体相互作用等信号通路，具有治疗前列腺肿瘤、乳腺肿瘤肺肿瘤、胃肿瘤、高血压、再灌注损伤和II型糖尿病等的潜能。结论：本研究通过网络药理学的方法分析了泽泻的药效物质基础，挖掘其治疗肿瘤、高血压、再灌注损伤、II型糖尿病等疾病的潜能。揭示了泽泻通过多组分、多靶点、多通路防治疾病的特点，为后续研究和临床应用奠定了理论基础。
Abstract: Objective: To explore the therapeutic potential and mechanism of Alismatis Rhizoma on multiple diseases. Methods: The chemical constituents and action targets of Alismatis Rhizoma were obtained by TCMSP database. The protein-protein interaction (PPI) network was constructed by using String database, and the PPI network was visualized by Cytoscape software to screen out the core targets. The enrichment of GO and KEGG pathways was analyzed by DAVID database. The therapeutic potential of Alismatis Rhizoma to multiple diseases was predicted by CTD database, and then ingredients-targets-pathways-diseases network of Alismatis Rhizoma was constructed by Cytoscape software, and its mechanism was analyzed. Results: 27 chemical constituents of Alismatis Rhizoma were screened, including Emodin, Alisol A, Alisol B 23-Acetate, Alismoxide and so on, corresponding to 73 targets. It mainly involves TNF signaling pathway, Type II diabetes mellitus, Hepatitis B, Neuroactive ligand-receptor interaction and other signal pathways. It has the potential to treat prostatic neoplasms, breast neoplasms, lung neoplasms, stomach neoplasms, hypertension, reperfusion injury, type II diabetes and other diseases. Conclusion: In this study, the pharmacodynamic material basis of Alismatis Rhizoma was analyzed by the method of network pharmacology, and its potential of Alismatis Rhizoma in the treatment of tumor, hypertension, reperfusion injury, type II diabetes and other diseases was explored. The characteristics of Alismatis Rhizoma through multi-components, multi-targets and multi-pathways to prevent and treat diseases were revealed, which laid a theoretical foundation for follow-up research and clinical application.
文章引用：詹家仪, 詹家国, 谭雅琴, 钟勰, 张瑶, 毛涵, 陈向云, 李尧锋. 基于网络药理学探究泽泻的治疗潜能及作用机制[J]. 药物资讯, 2022, 11(2): 127-135. https://doi.org/10.12677/PI.2022.112016

参考文献

[1] 国家药典委员会. 中国药典. 一部[M]. 北京: 中国医药科技出版社, 2020: 239.
[2] 刘珊珊, 郭杰, 李宗艾, 等. 泽泻化学成分及药理作用研究进展[J]. 中国中药杂志, 2020, 45(7): 1578-1595.
[3] 邢增智, 陈旺, 曾宇. 泽泻的化学成分与药理作用研究进展[J]. 中医药导报, 2017, 23(15): 75-78.
[4] 李佳欣, 陈思琦, 吴鑫宇, 等. 泽泻现代药理学研究[J]. 辽宁中医药大学学报, 2020, 22(2): 143-146.
[5] 汪春飞, 马良, 侯雪峰, 等. 泽泻醇提物对大鼠肾毒性及其分子机制的探究实验[J]. 中国中药杂志, 2016, 41(18): 3432-3438.
[6] 赵筱萍, 陆琳, 张玉峰, 等. 泽泻中肾毒性成分的辨析研究[J]. 中国中药杂志, 2011, 36(6): 758-761.
[7] 张宏达, 谢雪, 陈昱竹, 等. 泽泻毒性作用研究[C]//中华中医药学会. 中药炮制分会2011年学术年会论文集. 2011: 515-517.
[8] Wettersten, H.-I., Hakimi, A.A., Morin, D., et al. (2015) Grade-Dependent Metabolic Reprogramming in Kidney Cancer Revealed by Combined Proteomics and Metabolomics Analysis. Cancer Research, 75, 2541-2552. [Google Scholar] [CrossRef] 
[9] 李煦照, 朱魁元, 张帅男. 生物标签的探索: 中药药性研究的新模式[J]. 世界科学技术-中医药现代化, 2019, 21(1): 14-18.
[10] Luo, T.-T., Lu, Y., Yan, S.-K., et al. (2020) Network Pharmacology in Research of Chinese Medicine Formula: Methodology, Application and Prospective. Chinese Journal of Integrative Medicine, 26, 72-80. [Google Scholar] [CrossRef] [PubMed]
[11] 王璐. 聚氨酯泡沫固定化纤维素酶制备京尼平及其体外抗肿瘤活性[D]: [硕士学位论文]. 哈尔滨: 东北林业大学, 2016.
[12] Jang, E. and Lee, J.-H. (2021) Promising Anti-cancer Activities of Alismatis Rhizome and Its Triterpenes via p38 and PI3K/Akt/mTOR Signaling Pathways. Nutrients, 13, Article 2455. [Google Scholar] [CrossRef] [PubMed]
[13] Kwon, M.-J., Kim, J.-N., Park, J., et al. (2021) Alisma canaliculatum Extract Affects AGS Gastric Cancer Cells by Inducing Apoptosis. International Journal of Medical Sci-ences, 18, 2155-2161. [Google Scholar] [CrossRef] [PubMed]
[14] Huang, Y.-T., Huang, D.-M., Chueh, S.-C., et al. (2006) Alisol B Acetate, a Triterpene from Alismatisrhizoma, Induces Bax Nuclear Translocation and Apoptosis in Hu-man Hormone-Resistant Prostate Cancer PC-3 Cells. Cancer Letters, 231, 270-278. [Google Scholar] [CrossRef] [PubMed]
[15] 张爱凤, 盛玉青, 邹明畅. 泽泻醇B抗4T1乳腺癌细胞侵袭转移的体外研究[J]. 南京中医药大学学报, 2018, 34(2): 178-180.
[16] 徐永红. 泽泻醇B诱导胃癌细胞凋亡、抑制其侵袭、转移的机制研究[D]: [博士学位论文]. 沈阳: 中国医科大学, 2008.
[17] 马兵, 项阳, 李涛, 等. 泽泻对Lewis肺癌自发性转移的抑制作用及其机制研究[J]. 中草药, 2003, 34(8): 743-746.
[18] Wu, M.-Y., Yiang, G.-T., Liao, W.-T., et al. (2018) Current Mechanistic Concepts in Ischemia and Reperfusion Injury. Cellular Physiology and Biochemistry, 46, 1650-1667. [Google Scholar] [CrossRef] [PubMed]
[19] Francis, A. and Baynosa, R. (2017) Ischae-mia-Reperfusion Injury and Hyperbaric Oxygen Pathways: A Review of Cellular Mechanisms. Diving and Hyperbaric Medicine Journal, 47, 110-117. [Google Scholar] [CrossRef] [PubMed]
[20] Chen, W., Lv, L., Nong, Z., et al. (2020) Hyperbaric Oxygen Pro-tects against Myocardial Ischemia-Reperfusion Injury through Inhibiting Mitochondria Dysfunction and Autophagy. Molecular Medicine Reports, 22, 4254-4264. [Google Scholar] [CrossRef] [PubMed]
[21] 周广海, 岳华, 吴博, 等. 大黄素灌胃对原发性高血压大鼠心脏功能的改善作用及其机制[J]. 山东医药, 2019, 59(30): 29-32.
[22] Song, Y.-F., Zhao, L., Wang, B.-C., et al. (2020) The Circular RNA TLK1 Exacerbates Myocardial Ischemia/Reperfusion Injury via Targeting miR-214/RIPK1 through TNF Signaling Pathway. Free Radical Biology and Medicine, 155, 69-80. [Google Scholar] [CrossRef] [PubMed]
[23] Wang, X., An, F., Wang, S., et al. (2017) Orientin At-tenuates Cerebral Ischemia/Reperfusion Injury in Rat Model through the AQP-4 and TLR4/NF-κB/TNF-α Signaling Pathway. Journal of Stroke and Cerebrovascular Diseases, 26, 2199-2214. [Google Scholar] [CrossRef] [PubMed]
[24] 白小武. 大黄素对缺血再灌注大鼠肠粘膜屏障损伤的保护作用及机理研究[D]: [硕士学位论文]. 南京: 南京大学, 2012.
[25] 黄四周. 大黄素对脑缺血再灌注损伤大鼠的保护作用及机制研究[D]: [博士学位论文]. 福州: 福建中医药大学, 2018.
[26] 李忠. 大黄素对骨髓间充质干细胞移植治疗缺血性再灌注肾损伤的影响[J]. 中国组织工程研究, 2016, 20(14): 2052-2058.
[27] 林胜璋, 余耀军, 游涛, 等. 大黄素对大鼠肝脏缺血再灌注损伤的预防作用[J]. 中国中西医结合外科杂志, 2006, 12(2): 136-138.
[28] 吴斌. 大黄素对缺血再灌注损伤猪心肌保护及炎性反应机制研究[D]: [博士学位论文]. 武汉: 湖北中医药大学, 2009.
[29] 林裘震, 林炎柏. 糖尿病人群不同类型高血压的发病率及影响因素分析[J]. 江西医药, 2019, 54(12): 1569-1570, 1578.
[30] 陈永刚, 李云, 安利杰, 等. 高血压对糖尿病人群心脑血管事件的影响[J]. 中华高血压杂志, 2013, 21(4): 346-351.
[31] Petersmann, A., Müller-Wieland, D., Ulrich, A.M., et al. (2019) Definition, Classification and Diagnosis of Diabetes Mellitus. Experimental and Clinical Endocrinology & Diabetes, 127, S1-S7. [Google Scholar] [CrossRef] [PubMed]
[32] 管迎婷, 郑似楠, 王旭, 等. 泽泻治疗II型糖尿病的理论基础及研究进展[J]. 内蒙古医学杂志, 2019, 51(2): 153-155.
[33] Li, Q. and Qu, H. (2012) Study on the Hypoglycemic Activities and Metabolism of Alcohol Extract of Alismatis rhizoma. Fitoterapia, 83, 1046-1053. [Google Scholar] [CrossRef] [PubMed]
[34] 张伟云, 王明军, 刘华欣, 等. 环氧泽泻烯对II型糖尿病小鼠的降糖作用[J]. 中国药理学通报, 2019, 35(9): 1240-1244.
[35] 张伟云, 刘华欣, 王青, 等. 23-乙酰泽泻醇B对II型糖尿病小鼠血糖的影响[J]. 中国药理学通报, 2019, 35(5): 639-643.
[36] 钱增堃, 崔凡, 凌云熹, 等. 泽泻多糖对糖尿病大鼠肝脏糖脂代谢的影响[J]. 中国实验方剂学杂志, 2018, 24(11): 117-125.
[37] 张明丽, 陈吉全, 周新强. 泽泻多糖对II型糖尿病大鼠胰岛素抵抗及脂代谢紊乱的改善作用及机制研究[J]. 中国药房, 2018, 29(1): 42-45.
[38] 郝洁, 梁艳, 张瑞, 等. 大黄素改善糖脂代谢异常、糖尿病周围神经病变及糖尿病肾病的作用机制研究进展[J]. 中药药理与临床, 2020, 36(3): 265-272.
[39] 张传林. 大黄素对自发性高血压大鼠脑基底动脉平滑肌细胞大电导钙激活钾通道的作用[D]: [硕士学位论文]. 石河子: 石河子大学, 2014.
[40] 袁圆, 赵军, 高惠静, 等. 泽泻汤对肾性高血压复合高脂血症大鼠的影响[J]. 中国临床药理学杂志, 2013, 29(3): 205-207.
[41] 邹林蓁, 蒋海强, 周洪雷, 等. 泽泻在自发性高血压大鼠体内尿液代谢组学的研究[J]. 中华中医药杂志, 2018, 33(9): 4151-4154.
[42] 何红梅, 梅爱敏, 田河林, 等. 泽泻汤加味方对高盐诱导大鼠高血压肾功能损害的保护作用[J]. 山东医药, 2017, 57(17): 31-33.